Pharma: Page 20
-
Alexander Koerner / Stringer via Getty Images
Google bets on AI in the life sciences as ‘technology for a purpose’
A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.
By Alexandra Pecci • Oct. 10, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Tech wizards
The leaders paving the way to pharma’s future with state-of-the-art digital solutions.
By Karissa Waddick • Oct. 9, 2023 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Stock via Getty Images
Key upcoming events for pharma execs
Trade shows and events focused on the industry’s hot-button topics, technologies and trends.
By Meagan Parrish • Oct. 6, 2023 -
Stock via Getty Images
3 marketing tips for biotechs emerging from stealth
In a crowded biotech market, here’s how your company can stand out to investors.
By Karissa Waddick • Oct. 6, 2023 -
Permission granted by Dr. Emil Kakkis.
FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO
The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.
By Michael Gibney • Oct. 5, 2023 -
Stock via Getty Images
Drugmakers face uphill battle in Medicare negotiation suits
Judges have found fault with drug manufacturers’ First and Fifth Amendment arguments against the IRA’s drug pricing measures.
By Karissa Waddick • Oct. 4, 2023 -
Sarah Silbiger via Getty Images
5 FDA decisions to watch in the fourth quarter
The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.
By Ned Pagliarulo , Jonathan Gardner • Oct. 2, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Cancer care visionaries
Leaders shaping the future of oncology and cancer care through grit and determination in the face of one of healthcare’s greatest challenges.
By Michael Gibney • Oct. 2, 2023 -
Stock via Getty Images
3 recent FDA adcomm rejections — and why they matter
Decisions that could spell doom for drugs in development and already on the shelves.
By Meagan Parrish • Sept. 29, 2023 -
Photo illustration: Industry Dive; Getty Images
The PharmaVoice 100: Trailblazers
Leaders who are going where no biopharma executive has gone before and changing the industry along the way.
By Michael Gibney • Sept. 29, 2023 -
Tinnakorn Jorruang via Getty Images
How pharma marketers can reclaim the drug pricing narrative
As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.
By Karissa Waddick • Sept. 28, 2023 -
Drew Angerer via Getty Images
Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk
A recent report showed how pharma’s bonuses pale in comparison to other industries, but several execs still rake in hefty packages.
By Michael Gibney • Sept. 28, 2023 -
Mario Tama / Getty via Getty Images
Q&AInside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant
Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.
By Karissa Waddick • Sept. 27, 2023 -
iStock via Getty Images
Do humans have a place in pharma’s AI future?
From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.
By Michael Gibney • Sept. 26, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Standout execs
Leaders who’ve created unique strategies for thriving amid the heavy headwinds facing the industry.
By Meagan Parrish • Sept. 25, 2023 -
Stock via Getty Images
Elderly exclusion: Clinical trials still fall short enrolling older adults
Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.
By Kelly Bilodeau • Sept. 25, 2023 -
Morsa Images via Getty Images
Sponsored by AstellasFor Astellas’ CMO, accelerating innovation means working at the edge of your comfort zone
Scientific discovery through new, breakthrough modalities is essential to solve current and future global health challenges – but the path is not easy nor well-defined.
Sept. 25, 2023 -
iStock via Getty Images
Q&AAs the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
By Michael Gibney • Sept. 21, 2023 -
Jos Everts via Getty Images via Getty Images
What happened to ivermectin?
The saga of the anti-parasitic drug continues.
By Alexandra Pecci • Sept. 20, 2023 -
Rebecca Pifer/PharmaVoice
PBMs, PhRMA trade blame over drug costs in House hearing
Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee’s second PBM hearing on Tuesday.
By Rebecca Pifer • Sept. 19, 2023 -
Illustration: Deena So Oteh for Industry Dive
The 2023 PharmaVoice 100
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
By Julia Himmel • Sept. 19, 2023 -
iStock via Getty Images
Endangered horseshoe crabs could lead the charge in pharma’s animal-free future
An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.
By Kelly Bilodeau • Sept. 18, 2023 -
iStock via Getty Images
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
By Michael Gibney • Sept. 15, 2023 -
Courtesy of Sanofi
O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad
The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups.
By Karissa Waddick • Sept. 14, 2023 -
Stock via Getty Images
Catching up with 2022 PharmaVoice 100 honorees
Tapping into our growing community for expertise and inspiration.
By Meagan Parrish • Sept. 13, 2023
Previous
